Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants

Lorlatinib is approved worldwide as treatment for anaplastic lymphoma kinase‐positive and c‐ros oncogene 1‐positive non‐small cell lung cancer. The objectives of this phase 1, open‐label crossover study (NCT02569554) in healthy adult participants were to determine (1) the effects of the proton pump...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Huiping, O'Gorman, Melissa T., Nepal, Sunil, James, Lee P., Ginman, Katherine, Pithavala, Yazdi K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292600/
https://www.ncbi.nlm.nih.gov/pubmed/34288547
http://dx.doi.org/10.1002/cpdd.1000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292600/
https://www.ncbi.nlm.nih.gov/pubmed/34288547
http://dx.doi.org/10.1002/cpdd.1000

Ejemplares similares